Comment
. 2009 Jun 2;53(22):2105; author reply 2106-7.
doi: 10.1016/j.jacc.2008.12.075.
Different metabolic effects of selective and nonselective beta-blockers rather than mere heart rate reduction may be the mechanisms by which beta-blockade prevents cardiovascular events
- PMID: 19477370
- DOI: 10.1016/j.jacc.2008.12.075
Item in Clipboard
Comment
Different metabolic effects of selective and nonselective beta-blockers rather than mere heart rate reduction may be the mechanisms by which beta-blockade prevents cardiovascular events
J Am Coll Cardiol.
.
Free article
No abstract available
Comment on
-
Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension.J Am Coll Cardiol. 2008 Oct 28;52(18):1482-9. doi: 10.1016/j.jacc.2008.06.048. J Am Coll Cardiol. 2008. PMID: 19017516
Similar articles
-
Beta-blockers and hypertension.J Am Coll Cardiol. 2009 Jun 2;53(22):2105-6; author reply 2106-7. doi: 10.1016/j.jacc.2008.11.066. J Am Coll Cardiol. 2009. PMID: 19477369 No abstract available.
-
Beta-blocker-induced heart rate reduction: too simplistic to explain the deleterious effects of beta-blockers.J Am Coll Cardiol. 2009 Jun 2;53(22):2103-4; author reply 2106-7. doi: 10.1016/j.jacc.2008.12.074. J Am Coll Cardiol. 2009. PMID: 19477367 No abstract available.
-
Beta-blocker-induced heart rate lowering, cardioprotection, and hypertension.J Am Coll Cardiol. 2009 Jun 2;53(22):2104-5; author reply 2106-7. doi: 10.1016/j.jacc.2008.11.065. J Am Coll Cardiol. 2009. PMID: 19477368 No abstract available.
-
Current role of beta-blockers in the treatment of hypertension.Expert Opin Pharmacother. 2010 Nov;11(16):2599-607. doi: 10.1517/14656566.2010.482561. Epub 2010 Apr 28. Expert Opin Pharmacother. 2010. PMID: 20426702 Review.
-
[The metabolic effects of beta-receptor blockers. What is of practical importance in antihypertensive therapy?].Dtsch Med Wochenschr. 1992 May 29;117(22):875-9. doi: 10.1055/s-0029-1235345. Dtsch Med Wochenschr. 1992. PMID: 1350758 Review. German. No abstract available.
Cited by
-
Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?Curr Hypertens Rep. 2017 Apr;19(4):30. doi: 10.1007/s11906-017-0728-z. Curr Hypertens Rep. 2017. PMID: 28349377 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
